Novel drug-eluting stents in the treatment of de novo coronary lesions

@inproceedings{Capodanno2011NovelDS,
  title={Novel drug-eluting stents in the treatment of de novo coronary lesions},
  author={Davide Capodanno and Fabio Dipasqua and Corrado Tamburino},
  booktitle={Vascular health and risk management},
  year={2011}
}
Due to safety concerns in recent years, much effort has been devoted to improving the outcomes associated with drug-eluting stents (DESs). This review summarizes the current status of methodological and technical achievements reported in second-generation DES. Novel stents are described based on the component (the platform, the polymer, and the drug) that has undergone the most significant changes compared to earlier generation DES. An overview of the currently available evidence on the use of… CONTINUE READING

From This Paper

Figures, tables, and topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 12 extracted citations

In vitro and in vivo degradation of microfiber bioresorbable coronary scaffold.

Journal of biomedical materials research. Part B, Applied biomaterials • 2018
View 1 Excerpt

References

Publications referenced by this paper.
Showing 1-10 of 106 references

Sirolimus versus paclitaxel coronary stents in clinical practice.

Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions • 2011

A randomised comparison of novolimus-eluting and zotarolimus-eluting coronary stents: 9-month follow-up results of the EXCELLA II study.

EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology • 2010

APPOSITION II study results

RJ VanGeuns
Proceedings of TCT; • 2010
View 1 Excerpt

BIPAx bifurcation study: first results

RA Costa
Proceedings of Euro PCR; 2010 May 25–28; • 2010
View 1 Excerpt

BVS cohort A: four year results and lessons learned

JA Ormiston
Proceedings of TCT; • 2010
View 1 Excerpt

BVS cohort B: device design, 6-month update, and first report of the 12-month results

PW Serruys
Proceedings of TCT; • 2010
View 1 Excerpt

CARE II 8 month follow-up results with the CardioMind 0.014′′ Sparrow sirolimus-eluting nitinol stent system

AC Abizaid
J Am Coll Cardiol. 2010;56:B53 • 2010
View 1 Excerpt

First human use of the TAXUS Petal paclitaxel-eluting bifurcation stent.

EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology • 2010

Similar Papers

Loading similar papers…